Suppr超能文献

多电极射频消融治疗直径大于3cm且巴塞罗那临床肝癌分期为A至B2期的肝细胞癌患者的疗效

The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2.

作者信息

Lin Chen-Chun, Cheng Ya-Ting, Chen M Wei-Ting, Lin Shi-Ming

机构信息

Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Lin-Kuo, Chang Gung University, Taoyuan, Taiwan.

出版信息

Liver Cancer. 2016 Feb;5(1):8-20. doi: 10.1159/000367755. Epub 2015 Dec 15.

Abstract

Outcomes of hepatocellular carcinoma (HCC) lesions >3.0 cm in size including Barcelona Clinic Liver Cancer (BCLC) stage B after radiofrequency ablation (RFA) with a single electrode remain unsatisfactory. This study aimed to investigate the outcomes of RFA with multiple electrodes (ME-RFA) for HCC tumors 3.1-7.0 cm in size and BCLC stage B. This retrospective study included 70 consecutive patients with 58 medium- (3.1-5.0 cm) and 17 large- (5.1-7.0 cm) sized HCCs after ME-RFA using a controller. Outcomes in terms of complete response, primary technique effectiveness, local tumor progression, and overall survival were investigated. After 1-4 applications of ME-RFA, the rates of complete response and PTE in medium-sized tumors were 79.3% and 91.4%, respectively, and in large tumors were 76.5% and 94.1%, respectively. Overall, the major complication rate was 5.7%. After a median 21-month follow-up period, both two- and three-year estimated overall survival rates were above 80%. There were no significant differences in overall survival and local tumor progression rates between medium- and large-size tumors and among BCLC stages A, B1 and B2. A complete response to ME-RFA was the only significant factor associated with improved survival (p=0.008). In conclusion, ME-RFA can effectively treat 3.1-7.0-cm sized HCCs with a comparable outcome between medium- and large-size tumors and among BCLA stages A to B2.

摘要

对于大小>3.0 cm的肝细胞癌(HCC)病变,包括巴塞罗那临床肝癌(BCLC)分期为B期的病变,采用单电极射频消融(RFA)的治疗效果仍不尽人意。本研究旨在探讨多电极RFA(ME-RFA)治疗大小为3.1 - 7.0 cm且BCLC分期为B期的HCC肿瘤的疗效。这项回顾性研究纳入了70例连续患者,这些患者使用控制器接受ME-RFA治疗,其中有58个中等大小(3.1 - 5.0 cm)和17个大尺寸(5.1 - 7.0 cm)的HCC。研究了完全缓解、主要技术有效性、局部肿瘤进展和总生存率等方面的结果。在进行1 - 4次ME-RFA治疗后,中等大小肿瘤的完全缓解率和主要技术有效性分别为79.3%和91.4%,大尺寸肿瘤分别为76.5%和94.1%。总体而言,主要并发症发生率为5.7%。经过中位21个月的随访期,两年和三年的估计总生存率均高于80%。中等大小和大尺寸肿瘤之间以及BCLC分期A、B1和B2之间的总生存率和局部肿瘤进展率没有显著差异。对ME-RFA的完全缓解是与生存率提高相关的唯一显著因素(p = 0.008)。总之,ME-RFA可以有效治疗大小为3.1 - 7.0 cm的HCC,中等大小和大尺寸肿瘤之间以及BCLA分期A至B2之间的疗效相当。

相似文献

2
Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma.
Eur Radiol. 2021 Nov;31(11):8649-8661. doi: 10.1007/s00330-021-07729-9. Epub 2021 Apr 25.
4
Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study.
Scand J Gastroenterol. 2015 May;50(5):567-76. doi: 10.3109/00365521.2014.953572. Epub 2015 Jan 23.
6
[Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):256-60. doi: 10.3760/cma.j.issn.1007-3418.2012.04.006.
10
Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma.
J Gastroenterol Hepatol. 2017 Mar;32(3):695-700. doi: 10.1111/jgh.13586.

引用本文的文献

1
Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma.
Front Oncol. 2025 Jul 28;15:1530951. doi: 10.3389/fonc.2025.1530951. eCollection 2025.
8
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status.
J Interv Med. 2020 Oct 12;4(1):1-7. doi: 10.1016/j.jimed.2020.10.008. eCollection 2021 Feb.

本文引用的文献

1
Surgical and Locoregional Therapy of HCC: TACE.
Liver Cancer. 2015 Sep;4(3):165-75. doi: 10.1159/000367739. Epub 2015 Jul 10.
2
Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.
Liver Cancer. 2015 Sep;4(3):176-87. doi: 10.1159/000367740. Epub 2015 Jul 17.
3
Thrombocytopenia as an inexpensive, valuable predictor for survival in patients with hepatocellular carcinoma.
Scand J Gastroenterol. 2014 Dec;49(12):1507-8. doi: 10.3109/00365521.2014.962076. Epub 2014 Oct 2.
4
Local ablation for hepatocellular carcinoma in taiwan.
Liver Cancer. 2013 Apr;2(2):73-83. doi: 10.1159/000343843.
7
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
9
Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas.
Korean J Radiol. 2012 Jan-Feb;13(1):34-43. doi: 10.3348/kjr.2012.13.1.34. Epub 2011 Dec 23.
10
Local-regional treatment of hepatocellular carcinoma.
Radiology. 2012 Jan;262(1):43-58. doi: 10.1148/radiol.11110144.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验